Haikou, China – From January 13 to January 15, MicroPort Sorin CRM (Shanghai) Co., Ltd. ("MSC"), a joint venture of Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") and Italy-based Sorin Group, attended the 2017 International Cardiac Pacing Conference & the 9th China Cardiac Pacing Summit that was held in Haikou of Hainan Province and delivered a speech at the session of "R&D and Application of Domestically Made Cardiac Pacemaker" on January 14.
The congress was organized by China International Conference Center for Science and Technology and supported by Chinese Society of Pacing and Electrophysiology of Chinese Medical Association and the Heart Rhythm Special Committee of Chinese Medical Doctor Association, covering the clinical applications of cardiac implantable devices and treatment such as the cardiac pacemaker, the implantable cardioverter defibrillator, and the cardiac resynchronization therapy. The congress gathered many domestic and international specialists from the cardiac pacing industry to exchange ideas on complex clinical cases, new technologies as well as the latest advancement of clinical studies.
The International Cardiac Pacing Conference & the China Cardiac Pacing Summit has been held since 2007. It has become the most influential congress in the field of China's cardiac implantable device, which witnesses the development of several new technologies and at the same time promotes the development of China's medical device companies. During the opening ceremony of this year's congress, Professor Shu Zhang, President of the Heart Rhythm Special Committee of Chinese Medical Doctor Association, Professor Congxin Huang, President of Chinese Society of Pacing and Electrophysiology of Chinese Medical Association, Professor Dejia Huang, President-elect of Chinese Society of Pacing and Electrophysiology of Chinese Medical Association, delivered keynote speeches regarding the new progress of the cardiac arrhythmias field in 2016. The professional societies also listed ten milestones in the cardiac arrhythmias for the year 2016, through which the speakers reviewed the major advancements during the last year, not only to summarize the overall situation but also to establish a profound guideline for its development in the new year.
The development of domestically made pacemaker has always been the focus of the government and the industry, and one case in point is the session of "R&D and Application of Domestically Made Cardiac Pacemaker." In this session, MSC gave a speech introducing the R&D progress of MSC products and sharing the latest advancement of domestically made pacemakers with experts in attendance. In the following discussion section, several experts and MSC representative had active interaction on question interesting to the attendees.
As the domestically made pacemaker is gaining wider attention, MSC will take advantage of such trend to revolutionize China's pacemaker industry from "Made-in-China" to "Made-in-China + Innovated-in-China." MSC will strive for innovative product R&D and keep on enhancing its innovative capabilities in order to meet the needs of China's physicians and patients, and enable more patients to benefit from devices of world-class quality at more affordable price, and thereby to promote the use of domestically made pacemakers.